Participated · Seed · Jan 2026

Transition Metal Solutions is a mining-tech startup that creates low-cost, mostly inorganic additives designed to elevate entire microbial communities inside copper heap leaches rather than targeting single strains. In laboratory tests, its proprietary cocktail has lifted copper extraction to 90% versus the 60% achieved with conventional processes, and the team anticipates commercial recovery rates of 50-70% compared with today’s 30-60%. Each mine receives a tailored formulation following microbial assays, and the company aims to build predictive models that recommend treatments in advance. Management believes the technology can materially narrow the looming global copper supply gap by increasing output 20–30% from existing operations. Near-term plans include third-party validation by a respected metallurgy laboratory and a demonstration heap containing tens of thousands of tons of ore. The recently raised seed financing will fund these milestones and support further data collection to accelerate commercialization. The company has not yet disclosed revenue or customer figures.

Led · Series A · Nov 2025

MindImmune Therapeutics engineers therapies that target the immune system’s role in neurodegeneration, aiming to curb the neuroinflammatory processes that accelerate diseases like Alzheimer’s. Its research identifies and modulates specific biological pathways responsible for inflammation-driven neuronal damage. The company is advancing a new class of drug candidates designed to meaningfully change the course of neurodegenerative disorders rather than merely treating symptoms. With its latest capital, MindImmune plans to complete critical translational studies and prepare an Investigational New Drug (IND) submission to the FDA. The funding will also underwrite strategic planning for the program’s first clinical trials, bringing its lead candidates closer to human testing. Although revenue figures have not been disclosed, the $5 million infusion strengthens the firm’s financial runway as it moves from preclinical work toward early clinical development.

Participated · Series B · Sep 2025

Mojo Vision pioneers a wafers-in, wafers-out micro-LED platform intended to enable massively parallel optical I/O for AI infrastructure. Its integrated approach combines advanced 300mm CMOS circuitry, GaN-on-silicon micro-LED emitters, silicon photodetectors, multicore fiber bundles, custom micro-lens arrays, and proprietary software and tools. The company says this architecture enables thousands of optical channels in a compact footprint, delivering high bandwidth density, low energy per bit, and built-in redundancy. Mojo Vision has framed its technology as relevant to terrestrial data centers as well as distributed and orbital computing architectures where power, weight, and scalability matter. The company is based in Cupertino, Calif., and recently completed a $75 million financing the prior August before securing the $17.5 million strategic investment from Future Ventures. Mojo Vision is collaborating with Marvell to develop high-density micro-LED connectivity solutions as it advances commercialization.

Participated · Series A · Aug 2025

Sensorium Therapeutics develops brain and mental health treatments derived from natural products and driven by mechanistic neuroscience. Its proprietary SensAI platform integrates artificial intelligence, chemistry, and neuroscience to mine more than 50 million curated relationships across biology, pharmacology, clinical outcomes, and human experience. SensAI has produced three differentiated programs in under three years, led by SNTX-2643, a first-in-class precision serotonin modulator for anxiety. The company recently received FDA clearance of an IND for SNTX-2643, enabling first-in-human dosing beginning in Q3 2025. Sensorium describes SNTX-2643 as re-engineered from a natural product to enable rapid onset, reduce off-target side effects, and avoid sedation versus benzodiazepine-like drugs. Sensorium has built an IP estate extending into the 2040s and has made executive leadership changes concurrent with its clinical advancement. Sensorium Therapeutics is a Boston-based biotechnology company developing nature-inspired psychoactive medicines for mental health. The company leverages medicinal chemistry, neuroscience, and machine learning to discover and optimize compounds. Its initial asset is SENS-01 and it operates the Biodynamic Discovery Platform (BDP), a drug discovery engine that rapidly identifies, synthesizes, and enhances targeted molecules as novel therapeutics. Sensorium closed a $30 million Series A financing to advance SENS-01 and further develop the BDP. The company aims to use the proceeds to move those programs forward.

Participated · Seed · Aug 2025

Soil Action provides a platform that combines near-infrared spectroscopy (NIRS) with proprietary machine learning models to detect the form and availability of soil nutrients in real time. Its system reads soil as a tractor moves, processes the data on the fly, and builds layered maps of nutrient dynamics without a lab. The company plans to expand field trials with farmers across key U.S. row crop regions and pursue grower collaboration to validate agronomic impact. It intends to accelerate model development and validation while scaling field deployment and engineering teams. Soil Action also plans partnerships with OEMs, input providers, and agronomic platforms to integrate its sensing and modeling capabilities. The company is led by CEO Nate Storey and recently completed a seed financing to support these initiatives.